5 Analysts Have This to Say About Apellis Pharmaceuticals
Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:APLS) within the last quarter:
Yelp, Twilio, Atlassian, And Other Big Losers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording losses in the previous session.
Earnings Scheduled For November 7, 2022
Companies Reporting Before The Bell
• NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.
Apellis Announces Plans To Submit 24-Month Phase 3 Data To FDA For Pegcetacoplan NDA For Geographic Atrophy
Inclusion of the 24-month data has the potential to strengthen the product profile at launch, with minimal impact to launch timing
Submission will be a Major Amendment to the New Drug Application (NDA), extending
Provention Bio’s Second Try, Apellis’s Eye Disorder Drug Review, 3 Adcom Verdicts And More: November’s Key PDUFA Catalysts Biotech Investors Must Know
Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers
LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday’s Mid-Day Session
Gainers
LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
Investigator Says Apellis’ Lead Product Shows ‘First Direct Evidence Of Slowing Geographic Atrophy Lesion Growth’
Apellis Pharmaceuticals Inc (NASDAQ:APLS) announced new data from the 24-month Phase 3 OAKS study of pegcetacoplan for geographic atrophy (GA) secondary…